Major biochemical markers that act as predictors severity in patients with severe preeclampsia in ages 18 and 26 in the Niño Jesús Hospital of Barranquilla, 2014-2015
DOI:
https://doi.org/10.18041/2390-0512/bioc..2.2639Keywords:
Pre-eclampsia, Toxemic profile, Eclampsia, Severity, Hypertension and markerAbstract
The objective of this research was to determine which of the major biochemical markers that are part of the profile toxemic have greater association with severe pre-eclampsia in patients aged between 18 and 26 years in the Niño Jesus Hospital of Barranquilla in the period December 2014 to May 2015, is a retrospective descriptive correlational study; in this study 120 medical records of pregnant women who consulted in the Niño Jesus Hospital of Barranquilla which had pre-eclampsia in the aforementioned period were reviewed, they were classified by groups: Those that remained with a diagnosis of pre-eclampsia and patients that ended in severe pre-eclampsia. The variables analyzed were age, gestational age, blood pressure, risk factors and the development of preeclampsia, results toxemic profile (creatinine, LDH, transaminases, platelets, total, direct and indirect bilirubin, proteinuria random and within 24 hours). Toxemic profile components that had a close relationship with severe pre-eclampsia were the LDH (OR 3.35, 95% CI 0.41-26.84), platelets (OR 0.17 95% CI 0.028-1.08) and random proteinuria (OR 0.81 95% CI 0.16 -4.04). Given the general characteristics of pregnant women with severe pre-eclampsia study population the average age at presentation was 21.6 years appearing more frequently in patients aged between 18 and 20 years, most of these pregnant women in their first pregnancy (gilts); likewise the median gestational age at presentation was 36.5 weeks, with the largest group affected with gestational age between 35 and 39.6 weeks gestation, terminating pregnancy mostly surgically (cesarean). The most frequent risk factor was a family history of hypertension.
Downloads
References
2. Say D, Alison O, Ann-Beth M, Jane D, Metin G, Marleen T, et al. Global causes of maternal death: a WHO systematic analysis Lale. Lan-cet Glob Health 2014; 2:e323-33.
3. Determinantes sociales de la morbilidad y la mortalidad maternas. Acciones para superar las demoras I y II; UNFPA, Minsalud. Bogotá; 2014.
4. Objetivos de desarrollo del milenio, Colombia 2014, Programa de las Naciones Unidas para el Desarrollo (PNUD); 2014.
5. Protocolo de vigilancia en salud pública: Morbilidad extrema, Instituto Nacional de Salud, 19 mayo de 2015.
6. Cifuentes R. Obstetricia de alto riesgo, 6ta. edición, Distribuna Editorial Médica; 2006.
7. Beth P, Magee L, Dadelszen P. Assessment, surveillance and prognosis in preeclampsia. Best Practice & Research Clinical Obstetrics and Gynaecology. 2011; 25:449-62.
8. Von Dadelszen P, Payne B, Li J, Ansermino JM, Broughton Pipkin F, Cote AM, Douglas MJ et al. Prediction of adverse maternal outcomes in pre-eclampsia: Development and valida-tion of the fullPIERS model. Lancet. 2011; 377: 219-27.
9. Freitas LG, Alpoim PN, Komatsuzaki F, Carval-ho MD, Dusse LM. Pre-eclampsia: are plate-let count and indices useful for its prognos-tic. Hematology. 2013; 18(6):360-4.
10. Muller-Deie J, Schiffer M. Preeclampsia from a renal point of view: Insides into disease models, biomarkers and therapy. World Jour-nal of Nephrology. 2014; 3(4):169-81.
11. Thornton CE, Makris A, Ogle RF, Tooher JM, Hennessy A. Role of proteinuria in defining pre-eclampsia: Clinical outcomes for wo-men and babies. Clin Exp Pharmacol Physiol. 2010; 37(4):466-70.
Downloads
Published
Issue
Section
License
-
Reconocimiento — Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios<. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
-
NoComercial — No puede utilizar el material para una finalidad comercial.
-
CompartirIgual — Si remezcla, transforma o crea a partir del material, deberá difundir sus contribuciones bajo la misma licencia que el original.
- No hay restricciones adicionales — No puede aplicar términos legales o medidas tecnológicas que legalmente restrinjan realizar aquello que la licencia permite.